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In many regions of the world, tobacco use is
much more common among men than
among women. In China, for example, 63%
of men and only 3.8% of women are esti-
mated to be smokers (Yang et al. 1999).
Nevertheless, research has consistently shown
that many women are exposed to environ-
mental tobacco smoke (ETS), based both on
self-reports and on biologic indicators of
exposure (Windham et al. 1999a). Thus, the
effects of ETS on reproductive health are of
major public health importance.
Many studies have shown that active
smoking has adverse effects on a broad spec-
trum of reproductive outcomes, including fer-
tility (Curtis et al. 1997; Howe et al. 1985;
Hughes and Brennan 1996), time to preg-
nancy (Baird and Wilcox 1985; Bolumar et al.
1996; Curtis et al. 1997; Hull et al. 2000),
spontaneous abortion (Chatenoud et al. 1998;
Himmelberger et al. 1978; Kline et al. 1977),
and birth weight (Lindbohm et al. 2002;
Wang et al. 2002; Windham et al. 2000).
Active smoking has also been associated with
menstrual disturbances (Windham et al.
1999b). Some studies have suggested that
smoking may reduce levels of estrogen and
possibly progesterone, although results have
been mixed (Basu et al. 1992; Friedman et al.
1987; Jensen and Christiansen 1988; Key
et al. 1991; Khaw et al. 1988; Longcope and
Johnston 1988; MacMahon et al. 1982;
Michnovicz et al. 1986, 1988; Mochizuki
et al. 1984; Slemenda et al. 1989; Thomas
et al. 1993; Westhoff et al. 1996).
The evidence regarding adverse effects of
ETS on reproductive outcomes is less robust.
Studies have shown that ETS in the absence
of maternal smoking significantly reduced
infant birth weight (Martin and Bracken
1986; Rubin et al. 1986) and increased risk of
preterm birth (Hanke et al. 1999; Jaakkola
et al. 2001). Studies of the effects of ETS on
spontaneous abortion have been inconsistent
(Ahlborg and Bodin 1991; Chatenoud et al.
1998; Samet 1991; Windham et al. 1992,
1999c). Our studies have shown a signiﬁcant
dose–response relation between ETS exposure
and dysmenorrhea (Chen et al. 2000) and
early pregnancy loss (Venners et al. 2004).
In this study, we investigated the effect
of ETS exposure on the levels of urinary preg-
nanediol-3-glucuronide (PdG; the major
metabolite of progesterone) and estrone
conjugates (E1C; the major metabolite of
estrogen) in a cohort of women who partici-
pated in a reproductive health study in Anhui,
China. These women were followed prospec-
tively from the beginning of stopping contra-
ception and attempting to conceive, through
the end of pregnancy (or for up to 1 year with-
out conception). The women provided daily
diary records of vaginal bleeding and active
and passive smoking and also submitted daily
urinary specimens, which permitted us to
accurately determine the onset of each men-
strual cycle, the day of ovulation, and hormone
levels speciﬁc to cycle day relative to ovulation.
This was a homogeneous cohort of young
women, all of whom were newly married,
nulliparous, and employed full time in the
textile industry. Few of the women we studied
smoked cigarettes, but exposure to ETS was
very high because of the high prevalence of
smoking among their husbands. Few women
used pills or hormone shots as contraceptive
methods before entering the cohort. These
characteristics provided a unique opportunity
to study the adverse effects of ETS exposure on
reproductive hormones while minimizing
potential confounding factors.
Materials and Methods
Study population and procedures. This is part
of a large prospective reproductive health
study among women textile workers in
Anhui, China. The study protocols were
approved by the human subject committees
of the Chinese institutions involved in the
Address correspondence to X. Wang, The Mary Ann
and J. Milburn Smith Child Health Research Pro-
gram, Children’s Memorial Hospital and Children’s
Memorial Research Center, 2300 Children’s Plaza,
#157, Chicago, IL 60614 USA. Telephone: (312)
573-7738. Fax: (312) 573-7825. E-mail: xbwang@
childrensmemorial.org
This study is supported in part by grants 1R01
HD32505 from the National Institute of Child
Health and Human Development; 1R01 ES08337,
ES-00002, P01 ES06198, and 1R01 ES11682 from
the National Institute of Environmental Health
Sciences; and 20-FY98-0701 and 20-FY02-56 from
the March of Dimes Birth Defects Foundation.
The authors declare they have no competing
ﬁnancial interests.
Received 21 July 2004; accepted 13 January 2005.
Effect of Environmental Tobacco Smoke on Levels of Urinary 
Hormone Markers
Changzhong Chen,1 Xiaobin Wang,2 Lihua Wang,3 Fan Yang,4 Genfu Tang,4 Houxun Xing,4 Louise Ryan,5
Bill Lasley,6 James W. Overstreet,6 Joseph B. Stanford,7 and Xiping Xu1
1Department of Environmental Health, Harvard School of Public Health, Boston, Massachusetts, USA; 2Department of Pediatrics,
Northwestern University Feinberg School of Medicine and Children’s Memorial Hospital and Children’s Memorial Research Center,
Chicago, Illinois, USA; 3Center for Ecogenetics and Reproductive Health, Beijing Medical University, Beijing, China; 4Institute for
Biomedicine, Anhui Medical University, Anhui, China; 5Department of Biostatistics, Harvard School of Public Health, Boston,
Massachusetts, USA; 6Institute of Toxicology and Environmental Health and Department of Obstetrics and Gynecology, School of
Medicine, University of California, Davis, California, USA; 7Health Research Center, Department of Family and Preventive Medicine,
University of Utah, Salt Lake City, Utah, USA
Our recent study showed a dose–response relationship between environmental tobacco smoke
(ETS) and the risk of early pregnancy loss. Smoking is known to affect female reproductive hor-
mones. We explored whether ETS affects reproductive hormone proﬁles as characterized by urinary
pregnanediol-3-glucuronide (PdG) and estrone conjugate (E1C) levels. We prospectively studied
371 healthy newly married nonsmoking women in China who intended to conceive and had
stopped contraception. Daily records of vaginal bleeding, active and passive cigarette smoking, and
daily ﬁrst-morning urine specimens were collected for up to 1 year or until a clinical pregnancy was
achieved. We determined the day of ovulation for each menstrual cycle. The effects of ETS expo-
sure on daily urinary PdG and E1C levels in a ±10 day window around the day of ovulation were
analyzed for conception and nonconception cycles, respectively. Our analysis included 344 noncon-
ception cycles and 329 conception cycles. In nonconception cycles, cycles with ETS exposure had
signiﬁcantly lower urinary E1C levels (β = –0.43, SE = 0.08, p < 0.001 in log scale) compared with
the cycles without ETS exposure. There was no signiﬁcant difference in urinary PdG levels in cycles
having ETS exposure (β = –0.07, SE = 0.15, p = 0.637 in log scale) compared with no ETS expo-
sure. Among conception cycles, there were no significant differences in E1C and PdG levels
between ETS exposure and nonexposure. In conclusion, ETS exposure was associated with signiﬁ-
cantly lower urinary E1C levels among nonconception cycles, suggesting that the adverse reproduc-
tive effect of ETS may act partly through its antiestrogen effects. Key words: environmental tobacco
smoke, estrone conjugates (E1C), pregnanediol-3-glucuronide (PdG), prospective study, urinary
hormone levels. Environ Health Perspect 113:412–417 (2005). doi:10.1289/ehp.7436 available via
http://dx.doi.org/ [Online 14 January 2005]study and by the institutional review board of
the Harvard School of Public Health.
Detailed description of field data collec-
tion can be found elsewhere (Wang et al.
2003). Briefly, the eligibility criteria for the
ﬁeld enrollment were as follows: a) full-time
employed women workers, b) newly married,
c) 20–34 years of age, and d) had obtained
permission to have a child. All the women
were nulliparous. Women were excluded if
a) they were already pregnant before enroll-
ment, b) they had tried unsuccessfully to get
pregnant for at least 1 year in the past, and
c) they planned to quit/change jobs or to
move out of the city over the 1-year course of
follow-up. After obtaining informed consent,
the interviewer administered a baseline ques-
tionnaire, which included information on
contraceptive use, reproductive history, socio-
demographic characteristics, alcohol use, and
environmental and occupational exposures.
Beginning from the date of stopping use of
contraceptive methods, each woman kept a
daily diary to record sexual intercourse, vaginal
bleeding, medication, and medical conditions
and collected a daily ﬁrst-morning void urine
specimen for hormone assay. Daily diary
information and urine specimens were col-
lected for up to 12 months or until a preg-
nancy was clinically conﬁrmed.
The study was conducted in Anqing
Textile Mill during 1997 to 2000. The women
were recruited at the local Maternal and Child
Health Care Center. Of the total 1,006 newly
married women, 35 women were ineligible,
10 women refused, and 961 women were
enrolled; 99% of them did not smoke.
Hormone assays were performed for 387
women who had provided sufﬁcient diary and
urine samples and who did not smoke. A total
of 574 women were excluded from the current
analysis for the following reasons: 95 women
continued to use contraceptives; 121 women
declined diary or urine collection; 78 women
became pregnant because of contraceptive fail-
ure; 53 did not begin recording diaries and col-
lecting daily urine samples immediately after
stopping contraception; 8 were lost to follow-
up; 7 had menstrual irregularity at baseline; the
others did not have adequate diary and urine
samples.
Laboratory assays of urinary PdG, E1C,
and hCG. Urine specimens were stored in
our ﬁeld central laboratory at –20°C. Urinary
PdG and E1C levels were measured by
enzyme-based immunoassays (Munro et al.
1991). This method was very sensitive and sta-
ble. The minimum detection levels for PdG
and E1C were 3 ng/mL and 0.096 ng/mL,
respectively, and the coefficients of variation
measured from the repeated standards were
4.3 and 5.1% respectively. Urinary human
chorionic gonadotropin (hCG) levels were
analyzed by the immunoradiometric assay
(O’Connor et al. 1988). Urine creatinine lev-
els were measured according to the method of
Jaffe (Husdan and Rapoport 1968). All PdG,
E1C, and hCG values were normalized to cre-
atinine values to adjusted for urine concen-
tration. All the urine specimens from each
woman were analyzed and tested during a
single run and were assayed in duplicates.
Discrepancies of more than 3-fold between
duplicate assays were presumed to result from
technical error, and the assay was repeated.
The geometric mean of the replicates has been
used to summarize the results for each sample.
Statistical analysis. The central focus of
our analysis was to examine the independent
association between ETS exposure and uri-
nary PdG and E1C profiles among eligible
menstrual cycles. This required characteriza-
tion of following key variables: a) ETS expo-
sure status; b) ovulation status and the day of
ovulation in each cycle; c) conception status
in each ovulatory cycle; and d) modeling ETS
exposure in relation to menstrual-day–speciﬁc
urinary PdG and E1C levels.
ETS exposure status. As part of the daily
diary, information on daily exposure to ETS
was obtained. Two specific questions were
asked: a) Was there anyone who smoked
around you at home yesterday? b) Was there
anyone who smoked around you at your work-
place yesterday? If the woman answered “yes”
to either of the two questions, we coded the
day as having ETS exposure. For a specific
cycle, we counted the number of days in the
cycle and calculated the percentage of days
with ETS exposure. If it was greater than zero,
we coded the cycle as having ETS exposure.
Day of ovulation. We used two indepen-
dent methods to determine the day of ovula-
tion. We first used a previously published
E1C:PdG ratio algorithm (Baird et al. 1995).
Brieﬂy, this algorithm scans 5-day sequences
and looks for a 5-day sequence in which the
ratio value for the ﬁrst day is the highest of the
five, and the ratio values for each of the last
2 days are ≤ 40% of the ﬁrst-day value. The
second day in this sequence was designated the
day of ovulation or called day of luteal trans-
mission (DLT) for that cycle. This algorithm
had several limitations: a) The cut-point of a
60% decrease in E1C:PdG ratios in the pre-
ceding 2 days was derived from previously
published data and was subject to the sensitiv-
ity of laboratory methods for detecting PdG
and E1C; b) if there were missing data around
ovulation, the algorithm may fail to detect the
DLT; c) multiple DLTs may be detected in
one cycle.
To cross-validate the day of ovulation iden-
tiﬁed by the above method, we also applied a
two-piecewise regression model for daily PdG
levels to identify the day when PdG started to
rise (PdG rising point). This method is based
on the fact that PdG remains at a lower level
during follicular phase and rises after ovulation.
For each cycle, we assumed that log(PdG) val-
ues follow a normal distribution with constant
mean and variance before ovulation. After ovu-
lation, we modeled the log(PdG) with a normal
distribution with a quadratic mean function
and constant variance. For the day j of cycle i,
we modeled the log(PdG) value as:
Log (PdGij) = β0 if j ≤ k [1]
Log (PdGij) = β0 + β1
× (j –k) + β2
× (j –k)2 if j > k, [2]
where day k + 1 was assigned as the day of ovu-
lation. A “best ﬁt” (maximum R2) algorithm
was applied to identify the turning point k. We
compared the ovulation day identiﬁed by each
method. In the subsequent analyses, we only
included cycles in which the ovulation days
identiﬁed by the two different methods were
within ± 3 days. To be consistent, we used the
ovulation day derived from the PdG rising
point in the subsequent analysis.
Figure 1 illustrates the sampling frame and
steps we took to determine the day of ovulation.
Of the total 1,484 cycles from the 387 women,
804 cycles were selected for urinary hormone
analysis. We oversampled the cycles with early
pregnancy loss when we selected cycles. Sixteen
cycles were found without ovulation by algo-
rithms, and their anovulatory status was veriﬁed
by graphic examination. After determining the
day of ovulation by two different methods, we
excluded those cycles for which ovulation could
not be determined by one of the methods, or
in which comparison of the two methods
yielded a difference in ovulation day greater
than 3 days. As a result, a total of 673 cycles
from 371 women were included in the sub-
sequent analysis. We compared the cycles that
were included and excluded and did not ﬁnd
any signiﬁcant difference in terms of subjects’
demographic characteristics and ETS exposure
status (data not shown).
Conception status. A Bayesian model was
applied to determine conception status based
on daily urinary hCG values. Details can be
found elsewhere (Wang et al. 2003). Brieﬂy,
urine samples from 37 control women who
were not at risk for conception were collected
for serving nonconception controls cycles,
and urine samples from cycles ending with
clinical pregnancy were used for conception
control cycles. We assumed that square root
of hCG values followed a normal distribution
with a constant mean and variance before
conception. For postconception, we modeled
the square root of hCG with a normal distrib-
ution with a quadratic mean function and
constant variance, with the mean and variance
differing for clinical pregnancy and early
pregnancy loss. We chose noninformative
proper prior distributions for each parameter
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Monte Carlo methods. This model allowed
us to calculate a probability of conception for
each observed cycle. We defined conception
as a probability ≥ 0.9.
ETS exposure and urinary hormone
profiles. Once the ovulation day was identi-
ﬁed, we aligned the cycles according to the day
of ovulation. The average length of follicular
phase was 15.8 days with a range of 6 to
39 days and luteal phase was 15.0 days with a
range of 6 to 33 days. We focused on a 20-day
window starting from 9 days before ovulation
to 10 days after ovulation for comparison of
hormone profiles for the following reasons.
Most cycles had at least 20 days in length.
This ensures comparability of day-specific
hormones among cycles, and each cycle has
relatively equal contribution to the model
parameter estimation. Because the distribution
of values for urinary PdG and E1C were
strongly skewed toward the upper end, we
transformed daily urinary PdG and E1C to the
log scale for analysis. We calculated each day
mean log(PdG) and log(E1C) for ETS expo-
sure and nonexposure cycles. By inverse trans-
formation, we plotted the daily mean PdG
and mean E1C by ETS exposure status. We
further used linear regression models to exam-
ine the associations between ETS exposure
and daily log(PdG) and log(E1C) levels within
the defined window. Because E1C and PdG
levels ﬂuctuate during preovulatory and pos-
tovulatory phase, we adjusted the days relative
to ovulation using indicator variables. The
basic model was:
Yij = β0 + β1 × ETSi + β2 × (day = –9)
+ β3 × (day = –8) +…+ β20 × (day = 9)
Yij was log(PdG) or log(E1C) of day j in cycle i.
If a day had missing hormone data, that day
was not included in the analysis. Assuming that
the missing data were randomly distributed
within the window, the model should be valid.
The model was also adjusted for potentially
important covariates, including age (linear and
quadratic terms), body mass index (BMI; linear
and quadratic terms), education (high/middle),
shift work (yes/no), stress (low, moderate,
high), noise exposure (low, middle, high), and
dust exposure (low, middle, high). Because
there were multiple daily PdG and E1C obser-
vations from each woman, we applied a gener-
alized estimate equation (GEE) to adjust for
intrawoman correlation with SAS procedure
GENMOD (SAS Institute, Cary, NC, USA)
assuming an exchangeable working correlation
structure. We also explored the interaction
terms of ETS exposure status and the day indi-
cator variables and found no interactions.
Results
This is a young, nulliparous cohort. All the
women were newly married and were attempt-
ing to conceive. Of the 371 women included,
none smoke or drink alcohol. They all were
full-time textile workers. Table 1 presented the
characteristics of women who were included
in the analyses stratiﬁed by ETS exposure sta-
tus during the follow-up cycles. Women with-
out ETS exposure were similar to those with
ETS exposure in terms of age, height, weight,
BMI, education, and occupational exposures.
Article | Chen et al.
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Table 1. Characteristics of the 371 newly married young women by status of any ETS exposure, Anqing,
China (mean ± SD or %).
Characteristic Nonexposed (n = 25) ETS exposed (n = 346) p-Value
Age (years) 25.1 ± 1.8 24.9 ± 1.6 0.450a
Height (m) 1.6 ± 0.1 1.6 ± 0.1 0.481a
Weight (kg) 48.1 ± 6.3 49.3 ± 5.8 0.320a
BMI (kg/m2) 19.6 ± 2.1 19.8 ± 2.1 0.565a
Age at menarche (years) 14.5 ± 1.5 14.7 ± 1.4 0.562a
Cycle length (days) 30.0 ± 7.3 30.8 ± 5.4 0.547a
Follicular phase (days) 13.8 ± 6.6 15.9 ± 5.4 0.139a
Luteal phase (days) 16.2 ± 3.9 15.0 ± 3.1 0.118a
Shift work 96.0 95.7 0.936b
Education 0.177b
Middle school 60.0 63.1
≥ High school 40.0 37.9
Dust exposure 0.489b
Low 28.0 33.9
Moderate 28.0 36.8
Heavy 44.0 29.3
Noise exposure 0.665b
Low 24.0 26.6
Moderate 36.0 35.7
Heavy 40.0 37.7
Perceived stress 0.224b
Low 68.0 63.2
Moderate or high 32.0 36.8
Previous contraception 0.290b
Condom 43.5 29.8
Intrauterine device 0 4.0
Pill 0 0.9
Others 21.7 15.5
No contraception 34.8 49.8
ETS exposure
At home only 70.8
At work only 2.0
Both at work and at home 27.2
at-Test. bChi-square test.
Graph plots of daily
PdG and E1C profiles
(804 cycles)
E1C:PdG
ratio algorithm
Piecewise
modeling on PdG
758 cycles had one or multiple
5-day blocks determined
766 cycles had PdG rising
point determined
38 cycles had no PdG rising
point determined
730 cycles had ovulation
day determined by both
methods
16 cycles were found
non-ovulatory and were
verified by visual examination
398 cycles with a difference = 0
154 cycles with a difference = 1
81 cycles with a difference = 2
40 cycles with a difference = 3
Total 673 cycles
Included in the analysis
Excluded in the analysis 57 cycles with a difference > 3
46 cycles had no 5-day blocks
determined
Figure 1. Selection of cycles for inclusion in the analysis.The major occupational exposures in these
women were shift work, dust, and noise.
This analysis included 371 women who
contributed a total of 1,444 cycles. The aver-
age number of cycles followed was 3.8 (range,
1–16). Of the 1,444 cycles, 474 (32.8%)
cycles had conception. Of the 474 concep-
tions, 338 conceptions reached clinical recog-
nized pregnancy; 146 (30.8%) ended with
early pregnancy losses. The median time to
clinical pregnancy was three cycles.
Of the 673 cycles included in this study,
344 were nonconception cycles and 329 were
conception cycles; 76 cycles did not have ETS
exposure and 597 cycles had ETS exposure.
Figure 2 illustrates daily mean E1C and PdG
levels over the 20-day window of the menstrual
cycles, stratiﬁed by conception versus noncon-
ception cycles. Among the nonconception
cycles, ETS-exposed women had a consistently
lower daily urinary E1C level compared with
nonexposed women. Table 2 presents the crude
and adjusted associations between ETS exposure
and urinary PdG and E1C stratiﬁed by concep-
tion and nonconception cycles. ETS exposure
was found to be associated with a lower urinary
E1C levels (β = –0.43, SE = 0.08, p < 0.001 in
log scale) among nonconception cycles. Among
conception cycles, the association was not signif-
icant (β = –0.17, SE = 0.10, p = 0.085 in log
scale). There was no significant difference in
PdG level between nonexposed and exposed
women regardless of conception status.
Figure 3 plots the cycle mean urinary
PdG and E1C levels by the quintile of the
percentage of days having ETS exposure for
the cycle. The ﬁrst quintile had higher mean
E1C than did other quintiles among non-
conception cycles, but it did not show a clear
dose–response relationship.
Discussion
The potential adverse reproductive health
effects of ETS exposure are of great public
health concern even when the reproductive
effects of exposure to ETS are of modest
magnitude, because ETS exposure is so com-
mon and widespread. We recently reported a
dose–response relationship between ETS
exposure and early fetal loss in the same study
cohort (Venners et al. 2004). In this article we
reported a signiﬁcant effect of ETS exposure
on urinary E1C levels during nonconception
cycles but not during conception cycles. The
differential effect of ETS on urinary E1C levels
between conception and nonconception cycles
is interesting. One possible explanation is that
the E1C level was much higher during concep-
tion cycles than during nonconception cycles
and we did not have enough power to detect
the relatively small effect of ETS exposure
among conception cycles. This is one of the
few prospective studies examining the effect of
ETS exposure on urinary hormone markers,
and it provides new insight about potential
biologic mechanism by which ETS affects
reproductive outcomes and stimulates further
research in this area. Further studies are
needed to understand the interactions between
individual susceptibility and ETS exposure on
reproductive hormones.
Studying ETS raises unique challenges,
including exposure assessment and confound-
ing by active smoking (Seidman and Mashiach
Article | ETS exposure and urinary hormone markers
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Figure 2. Mean daily PdG (A,B) and E1C (C,D) levels in the 20-day window around ovulation by the status of ETS
exposure. Of 344 total nonconception cycles (A,C), 44 had no ETS exposure and 300 had ETS exposure; of 329
total conception cycles (B,D), 32 had no ETS exposure and 297 had ETS exposure.
Table 2. Associations between ETS and daily urinary PdG and E1C levels.
Crude Adjusted
Levels (pg/mL) β SE p-Value β SE p-Value
Nonconception cycles
Daily urinary log(E1C) –0.44 0.08 < 0.001 –0.43 0.08 < 0.001
Daily urinary log(PdG) –0.08 0.15 0.600 –0.07 0.15 0.637
Conception cycles
Daily urinary log(E1C) –0.14 0.09 0.09 –0.17 0.10 0.085
Daily urinary log(PdG) –0.07 0.14 0.654 –0.10 0.12 0.408
Sample size: nonconception cycles, 6,880 days (344 cycles); conception cycles, 6,580 days (329 cycles). Twenty indicator
variables were created to represent each day in the 20-day window and were put in the adjusted models along with other
covariates: age, age squared, BMI, BMI squared, education (high/middle), shift work (yes/no), stress (low, moderate,
high), noise exposure (low, middle, high), and dust exposure (low, middle, high). All models used the GEE method to adjust
for intrawoman correlation in cycles. Among the other covariates, shift work was found to be associated with a lower
log(E1C) levels (β = –0.25, SE = 0.12, p = 0.025); all other covariates were nonsigniﬁcant.1991). Several limitations need to be taken
into account when interpreting the results of
this study. All the women subjects were shift
workers in a textile industry and were young
and nulliparous. Therefore, caution is needed
before generalizing our ﬁndings to other popu-
lations. We did not have biochemical markers
of ETS exposures, and we relied only on
women’s self-reporting of both active and
passive cigarette smoking. The sample size of
non-ETS group was relatively small. The ovu-
lation days were estimated from urinary PdG
and E1C levels, and we included only the
cycles in which the ovulation days identiﬁed
by two methods were within ± 3 days, and this
may be still subject to errors. To address this
issue, we conducted sensitivity analysis by
changing the inclusion criterion of the cycles
in which the ovulation days identified by
two methods were the same, within ± 1 day,
within ± 2 days, within ± 4 or more days, and
repeated the analysis respectively. The results
did not change signiﬁcantly (data not shown).
Furthermore, ETS exposure at different days
of the menstrual cycle may have different
effects, and we did not have adequate sample
size to examine the potential timing effect of
ETS exposure.
Our study also has the following strengths:
The accurate determination of day of ovulation
is critical for appropriate comparisons of hor-
mone levels among individuals, given that
hormone levels change significantly over a
menstrual cycle. In this study, the day of ovu-
lation for each menstrual cycle was cross-
validated by two methods. This allowed us to
align the individual menstrual cycles accord-
ing to ovulation day. This was a prospective
study, and the ETS exposure status was based
on daily diary recording during the menstrual
cycle, which eliminated potential recall biases
commonly encountered in retrospective stud-
ies. In many previous studies, it was difﬁcult
to tease out the effect of active smoking versus
ETS exposure when the study population
contained a high proportion of women who
were exposed to both active and passive
smoking. In this study, all the women were
nonsmokers. In addition, these women were
homogeneous in terms of sociodemographic
characteristics and occupation; thus, this study
is less likely confounded by other environ-
mental exposures.
The observed association between ETS
exposure and urinary E1C level is biologically
plausible. Cigarette smoking had been sug-
gested to have antiestrogenic effects (Baron
et al. 1990; Spangler 1999). Evidence showed
that smoking reduces the risk of endometrial
cancer, increases the risk of osteoporosis, and
decreases the age of menopause. Our ﬁnding is
also consistent with a number of studies indi-
cating the effects of active smoking on estrogen
levels. MacMahon et al. (1982) reported lower
urinary levels of estrone, estradiol, and estriol
during the luteal phase of the cycle among the
premenopausal smokers compared with non-
smokers and ex-smokers and suggested that
smoking might reduce luteal estrogen produc-
tion. Subsequently, Mochizuki et al. (1984)
reported signiﬁcantly lower estrogen levels in
pregnant smokers compared with pregnant
nonsmokers. Basu et al. (1992) reported that
smoking and oral contraceptives independently
lower serum estradiol and progesterone concen-
trations in premenopausal women. Westhoff
et al. (1996) further reported that cigarette
smoking was associated with decreased mid-
cycle and luteal-phase estradiol levels.
Other studies of smoking and reproductive
hormones yielded negative results. Friedman
et al. (1987), in a study of 9 postmenopausal
smokers and 16 nonsmokers, found that
estrone, estradiol, dihydrotestosterone, and
dehydroepiandrosterone sulfate (DHEA-S) did
not differ between the two groups. Key et al.
(1991) further compared serum concentrations
of estradiol, progesterone, and DHEA-S,
and urinary excretion rates of six steroids of
predominantly adrenal origin, in a large cohort
of healthy premenopausal and postmenopausal
female smokers and nonsmokers, and found
that cigarette smoking does not affect serum
estradiol. Thomas et al. (1993) from a study
of 25 premenopausal cigarette smokers and
21 nonsmokers also reported no signiﬁcant dif-
ference in urinary concentrations of estradiol,
estrone, or estriol.
The possible explanations for these dis-
crepancies include inadequate sample size for
the negative studies, population differences,
and, most important, lack of control of the
timing of ovulation relative to the hormone
sampling. As is well known and also seen
from our data, reproductive hormones ﬂuctu-
ate over a menstrual cycle, and the timing of
the specimen collection is likely to be a criti-
cal factor in making comparisons among
groups or studies. It is conceivable that with-
out controlling for ovulation, it would be dif-
ficult to make valid comparison in hormone
levels between exposed and unexposed indi-
viduals. The selection of serum versus urinary
hormone markers and laboratory methods
may also account for some differences. In
addition, reproductive hormones are affected
by both physiologic and pathologic states,
including a woman’s age, BMI, pre- versus
postmenopause, ovulation versus nonovula-
tion cycle, conception versus nonconception
cycle, use of oral contraceptives, or other
exogenous sex hormones.
In summary, this prospective study indi-
cated that ETS exposure in demographically
homogeneous nonsmoking women was associ-
ated with signiﬁcantly decreased urinary E1C
levels throughout the nonconception men-
strual cycles, suggesting that the adverse repro-
ductive effect of ETS may act in part through
its antiestrogen effects.
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